Cardiology, Diabetes & Nephrology at the Limits Brazil

 

Apresentadores

Professor Otavio BerwangerProfessor Otavio Berwanger

Professor Otavio Berwanger (MD; PhD) is a cardiologist, clinical epidemiologist, and clinical trialist who has been working as Chair of the Executive and Steering Committees and Global Study Director of large-scale randomized clinical trials.

Professor Berwanger is currently the Director of the largest clinical trials unit and coordinating center in Latin America (the Academic Research Organization- ARO, of the Hospital Israelita Albert Einstein) in Sao Paulo-SP, Brazil. Hospital Israelita Albert Einstein is the leading hospital (#1) in Latin America and the #36 best hospital in the World according to Newsweek 2021. He coordinates a network of 169 Cardiovascular Research Sites in 11 countries (Brazil, Australia, New Zealand, Canada, China, Russia, Ukraine, Argentina, Mexico, Peru, and Colombia). Recently, Dr Berwanger also created and coordinates a network of several Hospitals in Brazil to conduct multicenter COVID-19 trials.

He was the main presenter of several large clinical trials in late-breaking clinical trial sessions at the American College of Cardiology Scientific Sessions, American Heart Association Scientific Sessions and European Congress of Cardiology-ESC. Professor Berwanger is usually an invited Speaker at major international events such as: American Heart Association Scientific Sessions, American College of Cardiology Scientific Sessions, European Society of Cardiology Congress, Society of Clinical Trials, Cochrane Symposium. Professor Berwanger has published manuscripts in major medical journals such as New England Journal of Medicine, Lancet, JAMA, Circulation, JACC, Annals of Internal Medicine, BMJ, and the European Heart Journal. Besides the design and coordination of large-scale trials.


Professor Perry ElliottProfessor Perry Elliott

Prof. Perry M. Elliott (H-index 94, 59909 citations) is Professor of Cardiovascular Medicine at University College London (UCL) and a Senior Fellow of the UK National Institute for Health Research (NIHR). He is director of the UCL Centre for Heart Muscle Disease, Head of Clinical Research at the Institute of Cardiovascular Science UCL and a consultant cardiologist in the Centre for Inherited Cardiovascular Disease at the Bart’s Heart Centre, St. Bartholomew's Hospital London, UK. He studied medicine at St. Thomas’s Hospital Medical School, London. After qualifying in 1987 he trained in general medicine, gaining membership of the Royal College of Physicians in 1991, and completed his general cardiology training at St. George’s Hospital Medical School, London. He was appointed as Senior Lecturer first at St. George’s Hospital in 1999 and then at UCL in 2003. He was promoted to Reader in Inherited Cardiac Disease in 2005 and became a full Professor at UCL in 2012.

He was elected as a Fellow of the European Society of Cardiology (ESC) in 2005, is Chairman of the ESC Heart Academy, past Chairman of the ESC Working Group on Myocardial and Pericardial Diseases (2010–2012) and the Executive Committee for the European Outcomes Research Programme registry on cardiomyopathies, chair of the ESC Guideline Task Force on Hypertrophic Cardiomyopathy, member of the Congress Programme Committee 2018-2020 and a member of the ESC Managerial Council 2018-2020. He is cardiovascular lead for the North Thames NHS Genomic Medicine Centre and President of Cardiomyopathy UK, Europe’s foremost charity for patients with heart muscle disease. From 2009 to 2013, he was Deputy Editor of The Heart Journal and is currently Deputy Editor for the International Journal of Cardiology.

Over the past 25 years, Prof. Elliott has established an international reputation in the field of heart muscle disease, authoring more than 350 peer-reviewed papers on the subject. He develops diagnostic standards, risk stratification tools and clinical service models based on some of Europe’s largest inherited heart disease cohorts, fostering industry collaborations in sequence interpretation, therapeutic trials and multicentre research partnerships.


Associated Professor Bruno GelonezeProfessor Bruno Geloneze

Bruno Geloneze obtained his MD in 1987 at the State University of Campinas (UNICAMP), Brazil, then completed a residency programme in endocrinology and metabolism at the same institution. His PhD involved studies on the metabolic effects of bariatric surgery. From 1998 onwards, his efforts have concentrated on the characterisation of the physiology of obesity and the metabolic and molecular effects of bariatric surgery. Additionally, he acts as Principal Investigator in several international clinical trials of new drugs for clinical forms of obesity and diabetes, including EMPA-REG, SCALE, CREDENCE and LEADER. He is the Co-ordinator of the epidemiological Brazilian Metabolic Syndrome Study (BRAMS) and Principal Investigator at the Obesity and Comorbidities Research Centre (OCRC) in Brazil. In 2002, Dr Geloneze became Assistant Professor of Endocrinology at the postgraduate medical school of the UNICAMP and dedicates part of his time to supervising endocrinology residents and PhD students in the field of obesity and diabetes. In 2006, Dr Geloneze founded the Laboratory of Investigation in Metabolism and Diabetes (LIMED). Dr Geloneze has published 137 peer-reviewed papers in prestigious medical journals in the fields of endocrinology, obesity and diabetes. Recent activities include the creation of the Advanced Course on Obesity Medicine at UNICAMP, contributing since 2015 to the formation of hundreds of experts in the fields of obesity and comorbidities in Brazil and Latin American countries.


Professor Borja IbáñezProfessor Borja Ibáñez

Borja Ibáñez, MD PhD combines research activities as Director of Clinical Research of the National Center for Cardiovascular Research in Spain with clinical activities as cardiologist at the University Hospital Fundación Jiménez Díaz. He was trained in Spain and in USA (Mount Sinai Heart, NY). His research is at the verge of basic and clinical arena, mainly in the fields of MI, heart failure, atherosclerosis and lately to cancer therapy-induced cardiotoxicity. He leads several studies in the field of primary and secondary prevention of atherosclerosis. Primary prevention studies aim at better identifying the risk of developing acute atherothrombotic events in asymptomatic subjects by imaging and other biomarkers means, while secondary prevention studies focus on better therapies to reduce subsequent events and to increase quality of life. He is an advanced imaging user, and has used magnetic resonance imaging to better understand pathophysiology of myocardial diseases (tissue characterization), to evaluate the benefits of cardioprotective therapies, and for improved risk stratification.

Borja Ibáñez, MD PhD combines research activities as Director of Clinical Research of the National Center for Cardiovascular Research in Spain with clinical activities as cardiologist at the University Hospital Fundación Jiménez Díaz. He was trained in Spain and in USA (Mount Sinai Heart, NY). His research is at the verge of basic and clinical arena, mainly in the fields of MI, heart failure, atherosclerosis and lately to cancer therapy-induced cardiotoxicity. He leads several studies in the field of primary and secondary prevention of atherosclerosis. Primary prevention studies aim at better identifying the risk of developing acute atherothrombotic events in asymptomatic subjects by imaging and other biomarkers means, while secondary prevention studies focus on better therapies to reduce subsequent events and to increase quality of life. He is an advanced imaging user, and has used magnetic resonance imaging to better understand pathophysiology of myocardial diseases (tissue characterization), to evaluate the benefits of cardioprotective therapies, and for improved risk stratification.


Dr Alberto Lorenzatti Dr Alberto Lorenzatti

Dr. Alberto J. Lorenzatti is Co-Director at the DAMIC Medical Institute / Rusculleda Foundation for Research, Teaching and Patient Care (Head of the Clinical Research network with more than 30 research sites in Argentina) and Chief of Cardiology at the Cordoba Hospital, Cordoba, Argentina (2017- 2021).

University Degrees: Medical Doctor, National Cordoba University, School of Medicine, 1980. Specialist in Cardiology, National Cordoba University, 1988. Certified Clinical Lipidologist, Argentine Lipid Society, 2014. Certified Medical Expert in Clinical Research and Pharmacology, Cordoba Province Medical Council, 2016.

Academic Background: Invited Professor of Internal Medicine, Cordoba Catholic University, Argentina (current), Teacher of Postgraduate Training in Cardiology, Córdoba National University, Córdoba Hospital (current).

Past President of the Argentine Federation of Cardiology (FAC)2020. Current Chair of the Americas Federation from the International Atherosclerosis Society (IAS) Co-Founder and Ex President of the Argentine Lipids Society (2003-2005); Member of the Board of Directors of the International Society of Cardiovascular Pharmacotherapy (ISCP), Co-Editor European Heart Journal (EHJ), Co-Editor European Cardiology Reviews (ECR).

Dr Lorenzatti is widely involved in clinical research and has served as a Country Lead and a Steering Committee member in many pivotal studies on cardiovascular diseases (Jupiter, Cantos, Fourier, Prominent, BetOnMace, SOUL and CLEAR among many others).

Publications: More than 500 Abstracts, Publications and Presentations at National and International levels.


Professor Paulo LotufoProfessor Paulo Lotufo

Paulo A Lotufo is an Internist and Epidemiologist, Professor of Medicine at the University of Sao Paulo, and Director of the Center for Clinical and Epidemiologic Research at the University of Sao Paulo. He got a Master (1990-93) and Doctoral (1993-96) and a postdoctoral fellowship at Division of Preventive Medicine at Brigham and Women's Hospital working on two longitudinal studies, the Physicians' Health Study and Women's Health Study (1997-99). He created with Professor Isabela Bensenor, the Center for Clinical and Epidemiologic Research that was involved initially testing bioequivalence of generic drugs and six pharmaceutical-sponsored trials related to the acute coronary syndrome. Further, in 2004, I was one of the entrepreneurs who created the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil).

He was invited to present ELSA-Brasil during international meetings such as International Epidemiologic Association, Anchorage, USA (2013); Society for Epidemiologic Research, Miami, USA (2016); and Scientific Sessions, American Heart Association, New Orleans, USA (2016). Three academic seminars were organized during the year of 2015 at Johns Hopkins University, Brown University, and Brigham and Women's Health). My thematic areas on ELSA-Brasil publications (only as first or senior author) have been subclinical atherosclerosis, hypertension, dyslipidemia.

Moreover, he had a permanent collaboration with the Global Burden of Diseases and the "NonCommunicable Diseases Risk Factor Collaboration (NCRisC).

At the same time, he was the Principal Investigator of two hospital-based registries dedicated to stroke and acute coronary syndrome and manage two randomized trials related to evaluating the effect of electric stimulation on depression whose results were published on the New England Journal of Medicine and JAMA. According to the rank by Web of Science/Clarivate, he was one most cited scientists worldwide. Most recently, I am involved Global Atrial Fibrillation Initiative organized by the University of Birmingham as the Brazilian principal investigator, and to establish strong ties with the cohorts organized in the International 100 K Cohorts Collaboration.

Dr Libby earned his medical degree at the University of California, San Diego, and completed his training in internal medicine and cardiology at the Peter Bent Brigham Hospital (now Brigham and Women’s Hospital). He also holds an honorary MA degree from Harvard University, and an honorary doctorate from the University of Lille, France.


Professor Marco MetraProfessor Marco Metra

Marco Metra is Professor of Cardiology and Director of the Institute of Cardiology of the Department of Medical and Surgical Specialties, Radiological Sciences and Public Health of the University and Civil Hospitals of Brescia, Italy.

He is Editor-in-Chief of the European Journal of Heart Failure, the official journal of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC), Senior Consulting Editor of the European Heart Journal and member of the Editorial board of many other scientific journals. His research activity is focused on treatment of heart failure and its comorbidities. He has had a leading role in multiple trials of new therapies in patients with heart failure.

He is the ex-officio member of the board of HFA, a fellow of HFA, ESC, the Heart Failure Society of America, a member of the Italian Society of Cardiology (SIC) and many other scientific societies.

He is author of more than 600 articles in peer-reviewed journals with a current google scholar H index of 87.


Professor Roberto Pecoits-FilhoProfessor Roberto Pecoits-Filho

Dr. Pecoits-Filho is a Senior Research Scientist at Arbor Research Collaborative for Health in Michigan, USA and a Professor of Medicine, Pontifical Catholic University of Paraná in Curitiba, Brazil. He is the current (2021-23) Chair of the Education Committee of the International Society of Nephrology. As a clinician, he has broad activities in Internal Medicine and Nephrology based at the University affiliated hospitals, where he was the Chief of the Department of Internal Medicine between 2010 and 2016, the Director of the Residency program in Nephrology from 2013 to 2016. Dr. Pecoits-Filho is the Principal Investigator for the study CKDOPPS, a multinational study on practice patterns and outcomes in chronic kidney disease and act as a Scientific Leader for clinical trials in the Americas with George Clinical.

Dr. Pecoits-Filho received his MD and trained in Internal Medicine and Nephrology in Curitiba, Brazil before completing a nephrology research fellowship at the University of Missouri, Columbia and a PhD from the University of Sao Paulo. He was a visiting scholar for extended periods at the Karolinska Institute (Sweden) and the George Institute (Australia), and has participated as a principal investigator, regional leader and in steering committees in multinational clinical trials. Dr. Pecoits-Filho served as a member of the Executive Committee of the International Society of Nephrology (ISN) (2017-2019), the SONG Initiative (2017-present) and KDIGO (2016-2018).


Professor Alan SalamaProfessor Alan Salama

Professor Alan Salama is a consultant in Nephrology and director of the UCL Department of Renal Medicine, at the UCL Faculty of Medical Sciences, rated as top in London for Medicine. He specializes in immunological kidney diseases, with expertise in vasculitis, autoimmunity and kidney transplantation.

Alan trained in Oxford and in London at The London Hospital, Guy’s Hospital and The Hammersmith Hospital, completing a PhD at the Royal Postgraduate Medical School and a post-doctoral period at Brigham and Women's Hospital, Harvard Medical School researching transplantation immunology and tolerance. He supervises a laboratory investigating immune mediated kidney disease in the context of transplantation and autoimmunity, attempting to find better ways of diagnosing and managing the immune dysfunction in patients.

He is actively involved in undergraduate and postgraduate education, is the UCL lead for renal academic trainees, teaching on and organizing various postgraduate courses, including the RCP Advanced Medicine course and Renal teach-ins as well as acting on UK Kidney week organizing committees.

He is the Secretary of the UK Renal Association, has served on the Kidney Research UK research Grants committee, and is an editor for Nephrology , Dialysis and Transplantation and the Clinical Journal of the American Society of Nephrology.


Professor Malcolm WalkerProfessor Malcolm Walker

Qualified in Medicine from the University of Birmingham. Clinical training in cardiology was at St Thomas’ Hospital London and Oxford. Appointed as Consultant Cardiologist and Physician at University College Hospital London (UCLH) in 1987 and Professor of Cardiology in 2019.

He co-founded with Prof Derek Yellon, the Hatter Cardiovascular Institute (HCI), which has an international reputation in laboratory and translational research, focusing on myocardial protection and producing >600 publications and over 70 MD and PhDs.

In 1990, in response to perceived local clinical need, he established a dedicated cardiology clinic for patients with disorders of haemoglobin, such as thalassaemia (TM) and sickle cell disease, at UCLH. Out of this service, in collaboration with Prof Dudley Pennell, the MRI T2* for non-invasive tissue iron measurement was developed. Clinical use of T2* has been credited with a >70% reduction in mortality in Thalassaemia. He has written the chapters on cardiac management of thalassaemia for the UK National Standards Framework and for the International Guideline published by TIF. He was an expert contributor to the AHA consensus statement on thalassaemia, published in Circulation 2013 and still the standard reference article for the cardiovascular care of TM patients.

In recent years research has focused on the cardiovascular complications of thalassaemia (TM) and the application of novel, abbreviated cardiac MRI sequences (rCMR). Trials of rapid rCMR protocols have been completed in Thailand, India, and Peru.

In 2016 he initiated the Cardio-oncology clinical service at UCLH. This is an expanding clinical service serving cancer patients with cardiovascular complications and now deals with >660 out-patient consultations per annum, and numerous in-patient consultations. It has been linked to a growing research effort established within HCI. He has published over 120 articles & have a Scopus H-index of 36.